REFERENCES
- Felmingham D, Gruneberg RN The Alexander Project Group. A multicentre collaborative study of the antimi-crobial susceptibility of community acquired lower respiratory tract pathogens 1992-93. The Alexander Project. J Antimicrob Chemother 1996; 38 (Suppl. A): 11-57.
- Esposito S, Noviello S, Ianniello F, Cuniato V. Activity of Moxifloxacin and 12 other antimicrobial agents against 216 Streptococcus pneumonaie isolates. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract E198. American Society for Microbiology, Washington, DC.
- Esposito S, Noviello S, Ianniello F. Erythromycin resis-tance in Group A 16-Haemolytic Streptococcus. Chemotherapy 1998; 44: 385–390.
- Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; (Suppl 74): 63-70.
- Rustige C, Wiedemann B. Pharmacodynamic differences of quinolones towards bacteria with identical MICs. In Program and Abstracts of the Seventeenth International Congress of Chemotherapy, Berlin, Germany, 1991. Poster 651.
- Dalhoff A, Ullmann U. Correlation between pharmaco-kinetics, pharamacodynamics and efficacy of antibacterial agents in animal models. Eur J Clin Microbiol Infect Dis 1990; 9: 479–487.
- Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoro-quinolone. Antimicrob Agents Chemother 1997; 41: 101–106.
- Brueggemann AB, Kugler KC, Doern GV. In vitro activ-ity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 1997; 41: 1594–1597.
- Visalli MA, Jacobs MR, Appelbaum PC. Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four 13-lactams. Antimicrob Agents Chemother 1997; 41: 2786-2789.
- Fass RJ. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrobial Agents Chemother 1997; 41: 1818-1824.
- Souli M, Wennersten CB, Eliopoulos GM. In vitro activ-ity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int J Antimicrob Agents 1998; 10: 23–30.
- National Committee for Clinical Laboratory Standards (NCCLS) Methods for dilution antimicrobial tests for bacteria that grow aerobically. Approved Standards. NCCLS Document M7A3. NCCLS, 771, Villanova, PA 19085, 1995
- Grasso S, Meinardi G, de Carneri I, Tamassia V. New in vitro model to study the effect of antibiotic concentration and rate of elimination of antimicrobial activity. Antimicrob Agents Chemother 1978; 13: 570–576.
- Wiedemann B. Pharmacodynamic activity of Moxifloxacin in an in vitro model against Gram positive and Gram negative pathogens. In Program and Abstracts of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 1999. Abstract P0773.
- Wiedemann B, Pfeil E, Wiegand I. Pharmacodynamic activity of grepafloxacin and macrolides in an in vitro model against respiratory tract pathogens. In Program and Abstracts of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 1999. Abstract P0776.
- Scaglione F, Piatucci JP, Tassi GF, Macarinelli G, Dugnani S, De Martini G, Fraschini F. Penetration of clar-ithromycin into oral and respiratory tissues. Drug Invest 1983; 6 (2): 104–109.
- Efthymiopoulos C. Pharmacokinetics of grepafloxacin J Antimicrob Chemother 1997; 40 (Suppl. A): 35-43.
- Craig WA, Dalhoff A. Pharmacodynamics of fluoro-quinolones in experimental animals. In: Quinolone Antibacterials, Kuhlmann J, Dalhoff A, Zeiler HJ, Eds. Berlin: Springer, 1998: 207-232.
- Hyatt JM, Nix DE, Stratton CW, Schentag JJ. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Entero-bacter cloacae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 1711–1716.
- Dahloff A. Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 1999; 43: 51–59.